Our goal is to combine diagnostic and therapeutic properties in a single molecule that can serve as a new theranostic drug to detect and treat certain tumor diseases
Theranostics is the combination of therapy and diagnostics. The aim is to enable the right therapy at the right time, in particular by means of a diagnosis that accompanies the therapy. In this way, a patient-specific therapy is to be realized.
Therapy + Diagnostic = Theranostic
Our current research area focuses on the development of metal-based radiopharmaceuticals equipped with diagnostic and/or therapeutic radionuclides as well as peptides/antibodies to address various tumor entities.
We research and develop bispidine-based radiopharmaceuticals for imaging and treatment of tumor diseases
A suitable building block for new theranostics is bispidine (3,7-biazacyclo[3.3.1]nonane). This chelator system allows the formation of thermodynamically stable and kinetically inert complexes for a variety of radiopharmaceutically relevant (radio)metal ions and also exhibits various functionalities to introduce peptides, antibodies and/or dyes (see Figure 1).
Bispidines with different ring sizes and different substituents are developed together with Prof. Peter Comba (University of Heidelberg) to make different radiopharmaceuticals accessible depending on the application. The research area covers the fields of inorganic as well as organic chemistry and analytics (purification and characterization techniques). In addition, detailed radiochemical, spectroscopic and biological studies are performed to elucidate the kinetics and mechanism of action and to investigate the behavior of these agents in vitro and in vivo.
Diagnostically relevant radionuclides are used for imaging techniques such as single photon emission computed tomography (use of gamma emitters e.g. indium-111, technetium-99m) and positron emission tomography (use of positron emitters e.g. copper-64, gallium-68). Therapeutically relevant radiometric ions emit alpha (e.g. actinium-225) or beta particles (e.g. lutetium-177) or Auger electrons (e.g. technetium-99m).
 P. Comba et al. Bispidines for radiopharmaceuticals. Dalton Trans. 2018, 47, 9202-9220. DOI: 10.1039/C8DT01108G
 P. Cieslik, M. Kubeil, H. Stephan, P. Comba. Bispidines and the use thereof, EP Patent 20 216 739.1, 2020.
 P. Comba, M. Kubeil et al. Bispidine Dioxotetraaza Macrocycles: A new class of bispidines for 64Cu PET imaging. Inorg Chem. 2014, 53, 6698–6707. DOI: 10.1021/ic500476u
Ina Kopp (PhD student since 2022)
Adrian Wünsche (PhD student since 2020, principal supervisor Prof. Dr. Jens Pietzsch)
Martin Gehmlich (Master student TU Dresden)
Former team members (click to open)
Karl Anger (Bachelor student HTW Dresden, 2021)
Christian Grafe (Bachelor student HTW Dresden, 2021)
Viktoriia Simonova (HZDR Sommer student, 2021)
Anamarija Pišpek (HZDR Sommer studentin, 2020)
Stepan Geri (Master student TU Dresden, 2019, joint supervision with Dr. habil C. Mamat)
Vera Sereda (HZDR Sommer Student, 2019)
Lily Southcott (exchange program of UBC/TRIUMF and HZDR, 2019)
Dr. Neha Choudhary (exchange program of UBC/TRIUMF and HZDR, 2019)
Dr. Thomas Kostelnik (exchange program of UBC/TRIUMF and HZDR, 2019)
Prof. Peter Comba, Ruprecht-Karls-Universität Heidelberg, Germany
Dr. Martin Hrubry, Institute of Macromolecular Chemistry, Czech Academy of Sciences, Czech Republic
Prof. Phil Andrews, Monash University, Australia
Prof. Bayden R. Wood, Monash University, Australia
A/Prof. Kellie Tuck, Monash University, Australia
Prof. Chris Orvig, The University of British Columbia, Canada
Prof. Roger Alberto, Universität Zürich, Schweiz